Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Last trade$31.52
Day change-$0.375 (-1.18%)
Day range$31.44 – $31.98
Volume124,575
Market cap$2.49B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.49B
Price / earnings
16.6×
Price / book
2.93×
Price / sales
1.27×
EV / sales
1.41×
EV / EBITDA
10.53×
Profitability
Earnings per share
$1.92
Return on assets
7.02%
Return on equity
17.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.68×
Current ratio
1.28×
Quick ratio
1.28×
Cash ratio
0.58×
Cash flow
Price / cash flow
10.98×
Price / free cash flow
11.89×
Free cash flow
$209.59M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$501.37M
$487.78M
$476.2M
$493.77M
$492.88M
$468.84M
$458.36M
$502.36M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$501.37M
$487.78M
$476.2M
$493.77M
$492.88M
$468.84M
$458.36M
$502.36M
Selling, general and administrative
$62.7M
$397.41M
$406.01M
$1.41B
$60.79M
$379.22M
$395.64M
$1.5B
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$436.16M
$430.86M
$434.54M
$444.98M
$424.82M
$408.98M
$426.26M
$464.31M
Operating income
$65.21M
$56.92M
$41.66M
$48.79M
$68.05M
$59.87M
$32.1M
$38.06M
Interest expense
-$8.13M
-$8.17M
-$8.27M
-$8.74M
-$8.94M
-$9.13M
-$9.15M
-$9.71M
Income before taxes
$64.99M
$54M
$38.84M
$45.6M
$87.78M
$54.97M
$28.09M
$33.33M
Income taxes
$18M
$14.16M
$9.27M
$11.91M
$16.07M
$15.71M
$7.35M
$2.85M
Net income
$46.99M
$39.84M
$29.57M
$33.68M
$71.71M
$39.26M
$20.74M
$30.48M
Net income attributable to common shareholders
$46.99M
$39.84M
$29.57M
$33.68M
$71.71M
$39.26M
$20.74M
$30.48M
EBITDA
$77.57M
$71.18M
$52.7M
$60.3M
$79.56M
$69.01M
$44.04M
$64.97M
Basic earnings per share
$0.61
$0.50
$0.37
$0.41
$0.85
$0.46
$0.25
$0.37
Diluted earnings per share
$0.59
$0.49
$0.36
$0.40
$0.84
$0.46
$0.24
$0.37
Recent news
Company coverage with links to the original publishers.
Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.
Pediatrix Medical Group (MD) is highlighted as a momentum stock with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The stock has shown strong recent performance, up 4.93% over the past week, 16.98% monthly, 19.55% quarterly, and 39.52% over the past year, outperforming the S&P 500. Earnings estimate revisions have been positive, with 2 upward revisions in the past two months for both current and next fiscal year, supporting the bullish outlook.
Pediatrix Medical Group has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates. The upgrade reflects positive sentiment about the company's earnings outlook, with analysts raising consensus estimates by 3.4% over the past three months. The company is expected to earn $2.37 per share for fiscal year 2026.
Zacks presents its investment research tools including Thematic Investment Screens covering 37 themes and Style Scores that complement the Zacks Rank system. The article explains how combining the Zacks Rank with Style Scores (Value, Growth, Momentum, and VGM) helps investors identify stocks with the highest probability of outperformance. Pediatrix Medical Group (MD) is highlighted as a #2 Buy with strong momentum metrics.
Pediatrix Medical Group reported Q3 2026 earnings of $0.72 per share, beating consensus estimates of $0.63 and surpassing revenue expectations. The company has outperformed the S&P 500 by 35.2% year-to-date. However, it received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, with the Medical Services industry ranking in the bottom 40% of sectors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.